{
    "clinical_study": {
        "@rank": "16802", 
        "arm_group": {
            "arm_group_label": "Chiauranib", 
            "arm_group_type": "Experimental", 
            "description": "Patients take a single dose of Chiauranib capsules for the  pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this dose-escalation study is to assess the safety and tolerability of\n      treatment with Chiauranib administered orally over a range of doses in patients with\n      advanced solid tumors."
        }, 
        "brief_title": "Phase I Study of Chiauranib in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histological or cytological confirmation of advanced solid tumor, including non-small\n             cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma,\n             gastrointestinal stromal tumor, gastric cancer, et al;\n\n          2. Patients with advanced solid tumors refractory to standard therapy or for which no\n             standard therapy exists;\n\n          3. Body mass index (BMI) is between 18 and 28;\n\n          4. Age: 18~65 years;\n\n          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n\n          6. Laboratory criteria are as follows:\n\n               1. Complete blood count: hemoglobin (Hb) \u2265100g/L (no blood transfusion within 14\n                  days); absolute neutrophil count (ANC) \u22651.5\u00d7109/L ; platelets >=100\u00d7109/L\n\n               2. Biochemistry test: serum creatinine <=1.5\u00d7upper limit of normal (ULN); total\n                  bilirubin\u22661.5\u00d7ULN; alanine aminotransferase / aspartate\n                  aminotransferase\u22661.5\u00d7ULN; fasting triglyceride (TG) <= 3.0 mmol/L; total\n                  cholesterol <= 7.75 mmol/L\n\n               3. Coagulation test: International Normalized Ratio (INR) < 1.5\n\n          7. Women of child-bearing potential should be non-lactating patients, and must agree to\n             use effective contraceptive methods prior to study entry, during study participation,\n             and up to 6 months following completion of therapy. A serum or urine pregnancy test\n             within 7 days before enrollment must be negative; Men must agree to use effective\n             contraceptive methods during study participation and up to 6 months following\n             completion of therapy;\n\n          8. Willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          1. Life expectation < 3 months;\n\n          2. Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, targeted\n             therapy and endocrine therapy, et al) within 4 weeks prior to study entry; Subjects\n             received nitrosoureas or mitomycin chemotherapy within 6 weeks prior to study entry;\n\n          3. Have uncontrolled or significant cardiovascular disease, including:\n\n               1. Myocardial infarction (< the last 12 months)\n\n               2. Uncontrolled angina (< the last 6 months)\n\n               3. Congestive heart failure (< the last 6 months), or Left Ventricular Ejection\n                  Fraction (LVEF) < 50% prior to study entry\n\n               4. History of any significant ventricular arrhythmias (e.g., ventricular\n                  tachycardia, ventricular fibrillation, or TdP)\n\n               5. History of significant QT interval prolongation, or Corrected QT Interval (QTc)\n                  > 450 ms prior to study entry\n\n               6. History of cerebrovascular accident\n\n               7. Symptomatic coronary heart disease requiring treatment with agents\n\n               8. Uncontrolled hypertension (> 140/90 mmHg) by single agent;\n\n          4. Have active bleeding , current thrombotic disease, or patients with bleeding\n             potential receiving anticoagulation therapy;\n\n          5. History of deep vein thrombosis or pulmonary embolism;\n\n          6. Have unsolved toxicities (> grade 1) from prior anti-cancer therapy;\n\n          7. Have clinical significant gastrointestinal abnormality, e.g., unable to swallow,\n             chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption\n             of oral agents, or patients undergone gastrectomy;\n\n          8. Have symptomatic brain metastasis;\n\n          9. History of organ transplantation;\n\n         10. Proteinuria positive;\n\n         11. Congenital or acquired immunodeficiency, active infections;\n\n         12. Any mental or cognitive disorder, that would impair the ability to understand the\n             informed consent document or the operation and compliance of study;\n\n         13. Any other condition which is inappropriate for the study in the opinion of the\n             investigators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122809", 
            "org_study_id": "CAR101"
        }, 
        "intervention": {
            "arm_group_label": "Chiauranib", 
            "description": "Take orally", 
            "intervention_name": "Chiauranib", 
            "intervention_type": "Drug", 
            "other_name": "CS2164"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chiauranib, advanced solid tumors, phase 1 study", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100021"
                }, 
                "name": "Cancer Hospital, Chinese Academy of Medical Sciences"
            }, 
            "investigator": {
                "last_name": "Yuankai Shi", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "zhangqian@chipscreen.com", 
            "last_name": "Qian Zhang"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Yuankai Shi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "dose-limiting toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "day 1-28"
            }, 
            {
                "measure": "Number of Adverse Events", 
                "time_frame": "An expected average of 8 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122809"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "pharmacokinetic profile of Chiauranib", 
                "safety_issue": "No", 
                "time_frame": "On day 1,8,15,22,25,26,27,28"
            }, 
            {
                "description": "clinical benefit rate (complete response (CR),partial response (PR),stable disease (SD) > 8 weeks),duration of response (DOR),time to progression (TTP), or tumor marker improvement, if appropriate", 
                "measure": "Evidence of benefit", 
                "safety_issue": "No", 
                "time_frame": "An expected average of 8 months"
            }, 
            {
                "description": "Plasma biomarkers: soluble vascular endothelial growth factor receptors (sVEGFR2), vascular endothelial growth factor (VEGF) Tumor tissue biomarkers: Aurora B, phospho-histone H3", 
                "measure": "Pharmacodynamic profile of Chiauranib", 
                "safety_issue": "No", 
                "time_frame": "On day 15,28"
            }
        ], 
        "source": "Chipscreen Biosciences, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chipscreen Biosciences, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}